CPD-002

• Description :

  CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis[1].

• UNSPSC :

  12352005

• Target :

  VEGFR

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/cpd-002.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CNC(C1=CC=CC=C1SC2=CC3=C(C(NC(C)=O)=NN3)C=C2)=O

• Molecular Formula :

  C17H16N4O2S

• Molecular Weight :

  340.40

• References & Citations :

  [1]Jiang F, et al., CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway. Int Immunopharmacol. 2024 Apr 20;131:111850.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2617376-08-4]